Aaron Levine

2.4k total citations · 1 hit paper
43 papers, 1.6k citations indexed

About

Aaron Levine is a scholar working on Physiology, Reproductive Medicine and Molecular Biology. According to data from OpenAlex, Aaron Levine has authored 43 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Physiology, 17 papers in Reproductive Medicine and 11 papers in Molecular Biology. Recurrent topics in Aaron Levine's work include Biomedical Ethics and Regulation (18 papers), Reproductive Health and Technologies (10 papers) and Pluripotent Stem Cells Research (9 papers). Aaron Levine is often cited by papers focused on Biomedical Ethics and Regulation (18 papers), Reproductive Health and Technologies (10 papers) and Pluripotent Stem Cells Research (9 papers). Aaron Levine collaborates with scholars based in United States, Australia and United Kingdom. Aaron Levine's co-authors include Robert Dietrich, Jeffery L. Dangl, Thomas Eulgem, Kay A. Lawton, J. E. Schmid, Richard Durbin, Dong D. Wang, Leslie E. Wolf, Dmitry M. Kissin and Sheree L. Boulet and has published in prestigious journals such as JAMA, Nucleic Acids Research and Nature Genetics.

In The Last Decade

Aaron Levine

42 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The transcriptome of Arabidopsis thaliana during systemic acquired resistance

2000 795 citations Aaron Levine et al. profile →

Peers

Countries citing papers authored by Aaron Levine

Since Specialization

Citations

This map shows the geographic impact of Aaron Levine's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aaron Levine with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aaron Levine more than expected).

Fields of papers citing papers by Aaron Levine

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aaron Levine. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aaron Levine. The network helps show where Aaron Levine may publish in the future.

Co-authorship network of co-authors of Aaron Levine

This figure shows the co-authorship network connecting the top 25 collaborators of Aaron Levine. A scholar is included among the top collaborators of Aaron Levine based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aaron Levine. Aaron Levine is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	An International Society for Cell & Gene Therapy working group short report on the future of expanded access to unapproved cell and gene therapies 2023 ·Cytotherapy ·Patricia J. Zettler, Laertis Ikonomou, Aaron Levine, Leigh Turner, Bambi Grilley, (unknown)	4
2	International Society for Cell & Gene Therapy Position Paper: Key considerations to support evidence-based cell and gene therapies and oppose marketing of unproven products 2023 ·Cytotherapy ·Laertis Ikonomou, Natividad Cuende, Miguel Forte, Bambi Grilley, Aaron Levine, Megan Munsie, John E.J. Rasko, Leigh Turner, Hamid Reza Bidkhori, Rachele Ciccocioppo, (unknown), Alok Srivastava, Daniel J. Weiss, Patricia J. Zettler, Bruce L. Levine	13
3	Navigating ethical challenges in the development and translation of biomaterials research 2022 ·Frontiers in Bioengineering and Biotechnology ·Michael D. Hunckler, Aaron Levine	13
4	Ethical issues and public communication in the development of cell-based treatments for COVID-19: Lessons from the pandemic 2021 ·Stem Cell Reports ·Leigh Turner, Megan Munsie, Aaron Levine, Laertis Ikonomou	10
5	A multiscale simulation framework for the manufacturing facility and supply chain of autologous cell therapies 2019 ·Cytotherapy ·Kan Wang, (unknown), (unknown), Ben Wang, (unknown), (unknown), (unknown), Aaron Levine, (unknown), Bruce L. Levine, Andrew D. Fesnak	22
6	Medical crowdfunding to access CAR T-cell therapy 2019 ·The Lancet Oncology ·(unknown), (unknown), Aaron Levine	11
7	State Performance in Pluripotent and Adult Stem Cell Research, 2009–2016 2018 ·Regenerative Medicine ·(unknown), Aaron Levine	1
8	Revisiting the Warnock rule 2017 ·Nature Biotechnology ·J. Benjamin Hurlbut, Insoo Hyun, Aaron Levine, Robin Lovell‐Badge, Jeantine E. Lunshof, Kirstin R.W. Matthews, (unknown), Alison Murdoch, Martín F. Pera, Christopher Thomas Scott, (unknown), Mary Warnock, Magdalena Zernicka‐Goetz, Qi Zhou, Laurie Zoloth	42
9	Differences in the utilization of gestational surrogacy between states in the U.S. 2017 ·PubMed ·Kiran M. Perkins, Sheree L. Boulet, Aaron Levine, Denise J. Jamieson, Dmitry M. Kissin	14
10	Medical societies, patient education initiatives, public debate and marketing of unproven stem cell interventions 2017 ·Cytotherapy ·Daniel J. Weiss, Leigh Turner, Aaron Levine, Laertis Ikonomou	18
11	Assessing State Stem Cell Programs in the United States: How Has State Funding Affected Publication Trends? 2015 ·Cell stem cell ·(unknown), Albert Cheng, Emily Jackson, (unknown), Aaron Levine	12
12	Navigating Bioethical Waters: Two Pilot Projects in Problem-Based Learning for Future Bioscience and Biotechnology Professionals 2015 ·Science and Engineering Ethics ·(unknown), Aaron Levine, Robert Kirkman, (unknown), Matthew J. Drake	6
13	Part 6: The role of communication in better understanding unproven cellular therapies 2015 ·Cytotherapy ·Lynn O’Donnell, Leigh Turner, Aaron Levine	11
14	Challenges in the translation and commercialization of cell therapies 2015 ·BMC Biotechnology ·(unknown), Aaron Levine	89
15	The Roles and Responsibilities of Physicians in Patients' Decisions about Unproven Stem Cell Therapies 2012 ·The Journal of Law Medicine & Ethics ·Aaron Levine, Leslie E. Wolf	45
16	Defining a risk-based approach to the design and technology usage of systems to attain IT availability and recoverability requirements 2011 ·(unknown), Aaron Levine, (unknown)	2
17	Policy Uncertainty and the Conduct of Stem Cell Research 2011 ·Cell stem cell ·Aaron Levine	27
18	Self-Regulation, Compensation, and the Ethical Recruitment of Oocyte Donors 2010 ·The Hastings Center Report ·Aaron Levine	43
19	The Oversight and Practice of Oocyte Donation in the United States, United Kingdom and Canada 2010 ·HEC Forum ·Aaron Levine	13
20	Trends in the geographic distribution of human embryonic stem-cell research 2004 ·Politics and the Life Sciences ·Aaron Levine	14

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact